BioWorld MedTech

Dec. 8, 2016

Abbott ready to bolt on Alere based on 'damaging business developments'

After nearly 10 months of waffling on a $5.8 billion decision, Abbott Laboratories might have spotted an emergency exit from its contract to buy Alere Inc. Read More

MIT team reduces beta amyloid plaques in mice using light therapy

Cures Act sails through Senate in 94-5 landslide

AdvaMed's Trunzo says least burdensome standard revived

EU sliding toward a compliance cliff as regulations advance

Attorney says outcome of hearing on CRISPR patents tough to predict

Abiomed Impella CP gets green light for high-risk PCI treatment

Appointments and advancements

Product briefs

Financings

Other news to note

MDD's Orthopedics Extra

Today's news in brief

BioWorld

BioWorld briefs for May 21, 2026.

Acid alpha-glucosidase molecular structure isolated on black

‘Detargeted’ targeted gene therapy improves activity in Pompe

BioWorld

A new strategy aims to improve gene therapy for Pompe disease by optimizing both the genetic component that restores the function of a deficient lysosomal enzyme...

News in brief

BioWorld Asia

BioWorld Asia briefs for May 19, 2026

WHO declares Ebola outbreak a public health emergency of international concern

BioWorld

The threat posed by the Ebola outbreak in the Democratic Republic of Congo has intensified, with the confirmation that it is caused by the Bundibugyo species of...

Nxera Pharma prepares and tests new GPR17 antagonists

BioWorld Science

Nxera Pharma UK Ltd. has identified new uracil nucleotide/cysteinyl leukotriene receptor (GPR17; P2Y-Like) antagonists potentially useful for the treatment of...